FDAnews
www.fdanews.com/articles/205037-merck-touts-positive-study-results-for-hiv-pill

Merck Touts Positive Study Results for HIV Pill

October 27, 2021

Merck’s investigational once-daily combination pill for HIV has shown positive results in two late-stage trials.

Both trials of the doravirine/islatravir pill in adults with HIV-1 infection who were on antiretroviral therapy regimens or Gilead Sciences’ Biktarvy (bictegravir/emtricitabine/tenofovir) met their primary efficacy endpoint of percentage of participants with HIV-1 RNA levels at or lower than 50 copies per milliliter of human plasma.  

Below 10,000 copies is considered a lower HIV viral load. A viral load that can't be detected, such as less than 20 copies, is the goal of HIV treatment.

The efficacy was comparable between the investigational combination and antiretroviral therapy regimens or bictegravir/emtricitabine/tenofovir at 48 weeks, Merck said. 

View today's stories